<DOC>
	<DOCNO>NCT00272662</DOCNO>
	<brief_summary>The purpose study evaluate safety , pharmacodynamics ( PD ) , pharmacokinetics ( PK ) multiple subcutaneously administer injection peginesatide anemic cancer participant receive chemotherapy .</brief_summary>
	<brief_title>Study Subcutaneously Administered Peginesatide Anemic Cancer Patients Receiving Chemotherapy</brief_title>
	<detailed_description>This Phase 2 , open-label , multi-center , sequential dose find study 6 treatment cohort receive chemotherapy 15 participant per cohort . The primary objective study determine dose peginesatide administer every 3 week ( Q3W ) subcutaneous injection associate hemoglobin increase ≥ 1 g/dL ≥ 50 % anemic cancer participant receive chemotherapy 9 week follow first dose .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<criteria>Participant inform investigational nature study give write , witness informed consent accordance institutional , local , national guideline Males female ≥ 18 ≤ 80 year age ; premenopausal female ( exception surgically sterile ) must negative pregnancy test screening ; sexually active must practice highly effective method birth control least 2 week prior study start , must willing continue practice birth control least 4 week last dose study drug . A highly effective method birth control define one result low failure rate ( i.e. , less 1 % per year ) use consistently correctly implant , injectables , combine oral contraceptive , IUDs , sexual abstinence ( acceptable practice lifestyle acceptable one sexually active practice abstinence duration study ) vasectomize partner Participants histologically confirm solid tumor malignancy lymphoma schedule receive least 9 week cyclic myelosuppressive chemotherapy study Hemoglobin value ≥ 8 &lt; 11 g/dL within 1 week prior administration study drug . ECOG Performance Status 02 One reticulocyte hemoglobin content ( CHr ) &gt; 29 picograms within 4 week prior study drug administration . One transferrin saturation ≥ 15 % within 4 week prior study drug administration . One serum red cell folate level low limit normal within 4 week prior study drug administration One vitamin B12 level lower limit normal within 4 week prior study drug administration One absolute neutrophil count ≥ 1.0 x 10^9/L within 1 week prior administration study drug One platelet count ≥ 75 x 10^9/L within 1 week prior administration study drug Life expectancy &gt; 6 month . Treatment erythropoiesis stimulate agent ( ESA ) past 90 day History failure respond ESA treatment Known antibody ESAs history pure red cell aplasia ( PRCA ) Acute chronic leukemia , myelodysplastic syndrome ( MDS ) , multiple myeloma Any previous plan radiotherapy 50 % either pelvis spine Known intolerance parenteral iron supplementation Red blood cell transfusion within 4 week prior study drug administration Known hemoglobinopathy ( e.g. , homozygous sicklecell disease , thalassemia type , etc . ) Known hemolysis History pulmonary embolism deep venous thrombosis ( DVT ) previous 2 year current therapeutic dos anticoagulant Known blood loss cause anemia Uncontrolled , symptomatic inflammatory disease ( e.g. , rheumatoid arthritis , systemic lupus erythematosus , etc . ) Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 2.5 time upper limit normal ; AST ALT &gt; 5 time upper limit normal liver metastasis present . Creatinine &gt; 175 micromoles per liter ( µmol/L ) History bone marrow peripheral blood cell transplantation Pyrexia/fever ≥ 39 °C within 48 hour prior study drug administration Poorly control hypertension , per Investigator 's judgment , within 4 week prior study drug administration ( e.g. , systolic ≥ 170 mm Hg diastolic ≥ 100 mm Hg repeat reading ) Epileptic seizure 6 month prior study drug administration Advanced chronic congestive heart failure New York Heart Association Class IV High likelihood early withdrawal interruption study Anticipated elective surgery study period History multiple drug allergy Exposure investigational agent within 1 month prior administration study drug plan receipt study period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>anemia</keyword>
	<keyword>cancer</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>chemotherapy induce anemia</keyword>
	<keyword>CIA</keyword>
	<keyword>hemoglobin</keyword>
	<keyword>Hb</keyword>
	<keyword>Hgb</keyword>
	<keyword>erythropoietin</keyword>
	<keyword>EPO</keyword>
	<keyword>erythropoiesis stimulating agent</keyword>
	<keyword>ESA</keyword>
	<keyword>Hematide</keyword>
	<keyword>Omontys</keyword>
	<keyword>peginesatide</keyword>
	<keyword>red blood cell</keyword>
	<keyword>red blood cell production</keyword>
</DOC>